- Home
- JG vs EQ Comparison
JG vs EQ Comparison
Compare JG & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JG
- EQ
- Stock Information
- Founded
- JG 2012
- EQ 2017
- Country
- JG China
- EQ United States
- Employees
- JG N/A
- EQ N/A
- Industry
- JG Computer Software: Programming Data Processing
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- JG Technology
- EQ Health Care
- Exchange
- JG Nasdaq
- EQ Nasdaq
- Market Cap
- JG 69.8M
- EQ 67.9M
- IPO Year
- JG 2018
- EQ 2018
- Fundamental
- Price
- JG $9.80
- EQ $1.91
- Analyst Decision
- JG
- EQ Hold
- Analyst Count
- JG 0
- EQ 2
- Target Price
- JG N/A
- EQ $1.00
- AVG Volume (30 Days)
- JG 7.4K
- EQ 16.0M
- Earning Date
- JG 08-28-2025
- EQ 08-14-2025
- Dividend Yield
- JG N/A
- EQ N/A
- EPS Growth
- JG N/A
- EQ N/A
- EPS
- JG N/A
- EQ N/A
- Revenue
- JG $48,999,972.00
- EQ $16,553,000.00
- Revenue This Year
- JG $10.90
- EQ N/A
- Revenue Next Year
- JG N/A
- EQ N/A
- P/E Ratio
- JG N/A
- EQ N/A
- Revenue Growth
- JG 18.82
- EQ N/A
- 52 Week Low
- JG $4.04
- EQ $0.27
- 52 Week High
- JG $20.94
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- JG 47.48
- EQ 70.45
- Support Level
- JG $10.08
- EQ $1.50
- Resistance Level
- JG $11.07
- EQ $1.90
- Average True Range (ATR)
- JG 0.35
- EQ 0.35
- MACD
- JG 0.09
- EQ 0.00
- Stochastic Oscillator
- JG 42.53
- EQ 65.63
About JG Aurora Mobile Limited
Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates and generates its revenue from the People's Republic of China.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.